Shreehas Tambe Appointed as CEO & Managing Director of Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) has announced Shreehas Tambe as its new CEO and Managing Director, effective April 1, 2026. The appointment follows approvals from the Nomination & Remuneration Committee and the Board. Tambe, the first CEO of Biocon Limited, will oversee the integrated biosimilars and generics platform. His responsibilities include strengthening Biocon's scale and global market competitiveness.

Kedar Upadhye assumes the role of Chief Financial Officer. This leadership transition arises from the full integration of Biocon Biologics Limited, streamlining Biocon's corporate structure. The company aims to lead in diabetes, obesity, oncology, and immunology, leveraging a portfolio including biosimilars and GLP-1 therapies.

Kiran Mazumdar-Shaw, Executive Chairperson, highlighted Biocon's strategic foresight in patient-centric growth. She praised Tambe's role in Biocon Biologics' transformation, including significant acquisitions and a global footprint expansion. Under his leadership, the company evolved into a top five global biosimilar entity valued at USD 5.5 billion. With extensive scientific and strategic expertise, Tambe is poised to guide the unified business to sustained global leadership.